YCBD
cbdMD, Inc. (YCBD) 10Y Growth Potential Analysis (2026)
No material changes this month.
Revenue Growth Drivers
No five-year revenue, EPS, or FCF CAGR is provided, so there is no evidence of repeatable compounding versus peers.
TTM ROIC is deeply negative at -27.9%, indicating current capital deployment is destroying value rather than funding scalable growth.
R&D intensity is only 0.09% of revenue, suggesting limited reinvestment into product expansion relative to peers with stronger innovation budgets.
Negative free-cash-flow yield and weak operating economics imply internally funded expansion capacity is materially weaker than profitable peer groups.
Market Tailwinds
No segment, share, or market-growth data is provided, so peer-relative demand tailwinds cannot be evidenced from the supplied filings metrics.
The absence of disclosed concentration metrics limits proof that YCBD can capture expanding demand faster than more diversified peers.
Negative profitability and weak cash generation suggest any market opportunity is not yet translating into durable revenue expansion.
Compared with peers that show positive returns and cash conversion, YCBD lacks evidence of a structurally advantaged growth environment.
Scalability Expansion
Capex-to-revenue of 8.7% is high for a business with negative returns, implying expansion is capital intensive rather than scalable.
Cash conversion cycle of 102 days indicates working capital is tied up for long periods, reducing reinvestment speed versus leaner peers.
Negative net debt is supportive, but the balance sheet alone does not offset weak operating scalability or prove compounding capacity.
With no evidence of operating leverage, YCBD appears less scalable than peers that can grow revenue without proportionate capital drag.
Constraints Limitations
Persistent negative ROIC is a structural constraint because additional growth would likely require more capital without proven economic payback.
High capex intensity and long cash conversion cycle limit the pace at which revenue can compound relative to asset-light peers.
Missing multi-year growth history prevents evidence of durable scaling, which keeps long-term growth confidence materially below stronger peer profiles.
Weak cash generation and zero interest coverage indicate limited internal funding capacity, constraining reinvestment-led expansion.
Overall Score
YCBD shows limited 10-year growth capacity because current economics are value-destructive, capital intensive, and unsupported by evidence of repeatable compounding versus peers.
Score Driver: Negative Roic
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on cbdMD, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
